Ponatinib for RAS-Driven Multiple Myeloma: Efficacy in the High-Risk VQ Myeloma Model

Evan Flietner

University of Wisconsin–Madison

Zhi Wen

University of Wisconsin–Madison

Adhithi Rajagopalan

University of Wisconsin–Madison

Oisun Jung

University of Wisconsin–Madison

Joshua Wiesner

University of Wisconsin–Madison

Xiaona You

University of Wisconsin–Madison

Yun Zhou

University of Wisconsin–Madison

Brock Kingstad-Bakke

University of Wisconsin–Madison

Natalie Callander

University of Wisconsin–Madison

Alan Rapraeger

University of Wisconsin–Madison

M. Suresh

University of Wisconsin–Madison

Fotis Asimakopoulos

University of California, San Diego

Jing Zhang (✉ zhang@oncology.wisc.edu)

University of Wisconsin–Madison

Research Article

Keywords: multiple myeloma, VQ model, re-purpose drug screen, ponatinib

Posted Date: February 21st, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1296881/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
[Read Full License](#)

Abstract

Multiple myeloma (MM) is a malignant plasma cell cancer. Mutations in RAS pathway genes are prevalent in advanced and proteasome inhibitor (PI) refractory MM. As such, we recently developed a VQ MM mouse model recapitulating human advanced/high-risk MM. Using VQ MM cell lines we conducted a re-purpose screen of 147 FDA-approved anti-cancer drugs with or without trametinib (Tra), a MEK inhibitor. Consistent with its high-risk molecular feature, VQ MM displayed reduced responses to PIs and de novo resistance to the Bcl2 inhibitor, venetoclax. Ponatinib (Pon) is the only tyrosine kinase inhibitor that showed moderate MM killing activity as single agent and strong synergism with Tra *in vitro*. Combined Tra and Pon treatment significantly prolonged the survival of VQ MM mice regardless of treatment schemes. However, this survival benefit was moderate compared to that of Tra alone. Further testing of Tra and Pon on cytotoxic CD8 T cells showed that Pon, but not Tra, blocked T cell function *in vitro*, suggesting that the negative impact of Pon on T cells may partially counteract its MM-killing synergism with Tra *in vivo*. Our study provides strong rationale to comprehensively evaluate agents on both MM cells and anti-MM immune cells during therapy development.

Introduction

Multiple myeloma (MM) is a plasma cell malignancy, representing 10% of hematological cancers and about 2% of all new cancer diagnoses (SEER 2021). Although many patients have benefitted from the introduction of immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and monoclonal antibodies, most patients are eventually refractory to these treatments [1]. Mutations in RAS pathway genes (e.g. *NRAS*, *KRAS*, and *BRAF*) are particularly prevalent among IMiD and/or PI refractory patients: 72% of them harbor mutations in one or more of these genes [2]. As such, we recently developed and characterized a MM mouse model, which is driven by two frequent genetic events identified in human MM, namely *MYC* overexpression and oncogenic *Nras*^{Q61R} (called VQ model) [3]. VQ MM mice fully recapitulate the biological and clinical features of human high-risk MM, including hyperproliferation, hyperactivation of MEK/ERK and AKT pathways downstream of RAS, extramedullary MM dissemination, upregulation of PD-1 and TIGIT immune checkpoint pathways, exhaustion of CD4 and CD8 T cells, and expression of the human UAMS-70 high-risk gene signature [3]. These MM phenotypes are serially transplantable in syngeneic recipients. We also derived two VQ cell lines from the primary myeloma cells for preclinical studies *in vitro*. In this study, we aim to develop novel target therapies using VQ MM cell lines and validate them in recipient mice transplanted with primary VQ-D1 MM cells.

Results

Re-purpose screening identifies de novo resistance of VQ MM cells to the BCL-2 inhibitor venetoclax.

We previously showed that an FDA-approved MEK inhibitor, trametinib (Tra), killed MM cells in a dose-dependent manner and downregulated surface PD-L1 expression *in vitro* [3]. In VQ-D1 MM recipient mice, Tra reversed exhausted cytotoxic CD8 T cell phenotypes (Figure S1) and prolonged their survival [3].

Therefore, we sought to identify new MEK inhibition-based combination therapies utilizing two VQ myeloma cell lines. A high-throughput screening assay was developed in which VQ 4938 cells were cultured in 384-well plates for 48 hours and viability was measured using the CellTiter-Glo luminescence assay. Cells treated with Tra served as a positive control for the assay, with DMSO treated cells as the negative control. Z' factor for the assay was consistently greater than 0.50, indicating assay reproducibility and consistency [4].

To expediate clinical testing, we initially focused on combining Tra with a library of 147 FDA-approved anti-cancer drugs provided by the National Cancer Institute (AOD IX panel). VQ 4938 cells were treated with the AOD IX panel drugs at concentrations of 100nM and 1000nM in the presence or absence of 10nM Tra (Figure 1A). Viability was measured as the relative change in luminescence compared to DMSO treated wells. Of note, 10nM Tra alone led to ~50% viability relative to DMSO control. Viability fold change of anti-cancer drug alone (X axis) versus viability fold change when the drug was combined with 10nM Tra (Y axis) was then plotted and analyzed via linear regression (Figure 1B). Area under the curve represents increased efficacy of compounds when combined with Tra.

The AOD IX panel includes many drugs approved for MM treatment. Based on their initial screening results as single agents (Table S1) and the knowledge of drug actions, these compounds were classified as positive, false negative, or negative (Figure 1C). False negative group included cyclophosphamide, a pro-drug that needs to be metabolized by the liver to be active *in vivo* [5], and IMiDs (e.g. lenalidomide), which are known to be ineffective against murine cells due to the species difference at the cereblon (Crbn) codon 391 [6]. Our *in vitro* validation of VQ response to lenalidomide (Figure S2) is consistent with its *in vivo* testing in Vk*MYC mice [7].

Interestingly, VQ 4938 cells showed de novo resistance to venetoclax, with an $IC_{50} > 1000nM$ in the primary screen (Table S1). We subsequently validated this result using two VQ cell lines and a broad range of drug concentrations (Figure 1D). Consistent with our primary screen result, the IC_{50} was not reached at 16mM in both VQ cell lines and estimated to be ~20mM. Venetoclax is considered one of the few targeted therapies for MM patients with t(11;14) translocations and/or high *BCL2:BCL2L1* and *BCL2:MCL1* gene expression ratios [8]. Therefore, we investigated the expression levels of *Bcl2* and *Mcl1* as well as *Bcl2* ratios to *Bcl2l1* and *Mcl1* in VQ MM cells. Not surprisingly, RNA-Seq analysis of primary VQ MM cells and control plasma cells [3] showed that *Bcl2* and *Mcl1* expression levels (Figure 1E) and both expression ratios (Figure 1F) were lower in VQ MM cells than those in control plasma cells. Together, our data suggest that VQ MM cells may not depend on *Bcl2* for survival and are thus de novo resistant to venetoclax.

Proteasome inhibitors show limited efficacy in the VQ model.

The Positive group included PIs (e.g. bortezomib [Btz] and carfilzomib [Cfz]), HDAC inhibitors (e.g. panobinostat and romidepsin), and several chemotherapy agents (e.g. vinblastine sulfate and vincristine sulfate) (Fig. 1C and Table S1). Again, these results were validated using both VQ 4935 and 4938 cell

lines in dose response tests (Figures S3, S4A, and S4D). In comparison to human myeloma cell lines [9], both VQ MM cell lines displayed increased resistance to Btz and Cfz based on their IC₅₀ values (~9nM and ~60-70nM respectively, Figures S4A and S4D). This is in line with clinical data showing patients with *NRAS* mutations have reduced Btz sensitivity [10]. Because PIs are used in all lines of MM treatment, we further explored them *in vivo*. In our previous study [3], we used Btz in the VQ model as a single agent following a treatment scheme established with the Vk*Myk model [7]. However, a significant proportion of treated mice died soon after the treatment, suggesting that VQ MM mice may not tolerate this treatment scheme very well. Therefore, we adjusted it based on the current clinical practice in human patients and found that this revised scheme showed transient effectiveness in controlling VQ growth *in vivo* (Figure S4B) and provided a moderate but significant increase in survival (Figure S4C).

To further boost the survival benefit, we used Cfz as part of a combination therapy regimen with dexamethasone (Dex), Tra, and GSK525762 (GSK), a pan-BET inhibitor [11]. We previously showed that combined Tra and GSK prolonged the survival of VQ MM mice better than single agents alone [3]. In this new combination treatment, Cfz and Dex were administered once a week for two weeks, followed by one week of daily treatment with Tra and GSK. Although combo therapy slowed VQ growth after the first treatment cycle (Figure S4E), it did not significantly prolong the survival of VQ-bearing mice (Figure S4F). Overall, our data show that PIs only provide short-term disease control in the VQ model.

Combination trametinib and ponatinib treatment are synergistic against VQ myeloma cells in vitro.

Screening of the AOD IX panel identified 1000nM ponatinib (Pon) as having high synergy with Tra against VQ myeloma cells (Figure 2A and 2B). Pon is a multi-tyrosine kinase inhibitor (TKI) currently approved for second-line treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia [12]. Interestingly, no significant efficacy was observed for other TKIs as single agents or in combination with Tra (Figures 2A and 2B). Although dose-response testing of VQ 4935 and 4938 cell lines confirmed that Pon had limited effect as a single agent (Figure 2C), it showed strong synergy with Tra against both VQ cell lines based on ZIP delta score analysis [13] (Figure 2D and 2E) and Combination Index calculation [14] (Figure S5). Of note, this synergy appeared to be more prominent at higher concentrations of Pon (>250nM).

Combination trametinib and ponatinib significantly prolongs survival of VQ mice in two different treatment regimens.

Because Pon is available as an oral drug in clinic and has not been evaluated in MM before, it was of interest to determine its *in vivo* efficacy alone and in combination with Tra. VQ-D1 MM cells were transplanted into sub-lethally irradiated recipient mice as previously described.³ Once MM was established, recipients were divided into 4 groups with comparable gamma-globulin to albumin (G/A) ratios and similar complete blood count (CBC) parameters and treated with vehicle, Tra, Pon, and combined Tra and Pon (Figure 3A and S6). Twenty-one days after treatment, all four groups of mice showed increased but indistinguishable G/A ratios (Figure 3B) and the overall CBC results were

unchanged (Figure S6). Consistent with our *in vitro* analysis, Pon treatment did not prolong the survival of VQ-D1 MM mice, while both Tra and combined Tra and Pon treatments did (Figure 3C). Although combination treated mice had the longest overall survival, we did not observe significant difference between Tra- and Tra/Pon-treatment groups.

We subsequently sought to determine if increasing the Tra dosage would significantly prolong the survival of Tra/Pon treated mice. To combat against the potential cumulative toxicity associated with higher Tra dose, we also took the 3-week on and 1-week off schedule as in myeloma patient treatment. In a second *in vivo* experiment, recipients were divided into 3 groups with comparable G/A and CBC parameters and then treated with vehicle, Tra alone, or combination Tra/Pon in 28-day cycles (Figure 3D). Once again, no significant difference was observed in G/A ratios between groups after one treatment cycle (Figure 3E). Interestingly, although no survival benefit was observed with single agent Tra treatment, combo treated mice had significantly prolonged survival compared to the vehicle-treated group (Figure 3F).

Ponatinib, but not trametinib, inhibits CD8 T cell proliferation and activation *in vitro*.

We investigated if the discrepancy between *in vitro* and *in vivo* combo treatment outcomes results from the drug effects on cytotoxic CD8 T cells, which play an important role in anti-MM immunity [15]. To test this idea, CD8 T cells were isolated from spleens of wildtype B6 mice, stained with CFSE dye, and activated via α -CD3/ α -CD28 antibodies in the presence of Tra or Pon for 48 hours (Figure 4A). Tra treatment did not cause significant reduction in T cell proliferation as measured by CFSE tracing (Figure 4B) and T cell activation as demonstrated by surface expression of CD69, DNAM-1, and PD-1 (Figure 4C-E). By contrast, Pon treatment completely inhibited T cell proliferation and activation (Figure 4B and 4C). Our results are consistent with prior studies showing that ponatinib and related BCR-ABL TKIs (e.g. dasatinib, imatinib) impair T cell function and viability in a dose-dependent manner [16–18].

Discussion

While the introduction of IMiDs, PIs and monoclonal antibody treatments has revolutionized MM therapy, most patients still develop drug-refractory disease and eventually die of myeloma [1]. RAS pathway hyperactivation is a common molecular event in progressive myeloma, with almost 75% of drug-refractory myeloma patients harboring mutations in *NRAS*, *KRAS*, or *BRAF* [2]. In this study, our group used the recently developed VQ model of high-risk myeloma as a platform to develop new treatment regimens. To assess the effectiveness of existing MM therapies against VQ myeloma and expedite clinical testing, we carried out a re-purpose screen of 147 FDA approved anti-cancer compounds against VQ cells *in vitro* (Figure 1A). We found that VQ cells showed *de novo* resistance to venetoclax (Figure 1D), likely owing to low Bcl2:Bcl2l1 and Bcl2:Mcl1 gene expression ratios (Figure 1F) [8]. In addition, VQ cells showed increased resistance to Btz (Figure S4A) and Cfz (Figure S4D) compared to human MM cell lines *in vitro* [9]. Limited response to PI treatment was also observed *in vivo*, either as single agent (Figure S4C)

or as part of multi-drug treatment regimen (Figure S4F). This is not altogether unexpected, as resistance to single agent Btz has been observed in patients harboring *NRAS* mutations [10].

As a single agent, Tra displays dual effects on MM cells and T cells. Tra kills MM cells in a dose-dependent manner and downregulates surface PD-L1 expression *in vitro* [3]. Tra treatment of purified splenic CD8 T cells *in vitro* did not significantly impact on their proliferation (Figure 4B) and activation (Figure 4C-4E). These *in vitro* T cell results are consistent with our prior study that downregulation of RAS/ERK signaling in *Kras*^{-/-} T cells does not affect CD8 T cell-mediated anti-leukemia activity *in vivo* [19]. In VQ-D1 MM recipients, Tra reversed exhausted cytotoxic CD8 T cell phenotypes (Figure S1) and prolonged their survival [3]. Of note, low dose, continuous Tra treatment (Figure 3C) worked better than high dose, on/off Tra treatment *in vivo* (Figure 3F). This observation is consistent with cancer patients treated with Tra [20].

Interestingly, among all the TKIs in the AOD IX panel, only Pon showed moderate cell killing at 1mM as single agent (Figure 2B) and strong synergism with Tra at concentrations above 250nM (Figure 2D and 2E). The difference between Pon and other TKIs may be due to their differential targeting profiles. Unlike other TKIs in this screen, Pon is a potent pan-FGFR inhibitor with IC₅₀ values <100nM (21). In human MM, FGFR3 is overexpressed in the t(4;14) high-risk subset as the translocation places FGFR3 expression under the control of the heavy chain immunoglobulin promoter on chromosome 14 [22]. However, FGFRs are not overexpressed or mutated in VQ MM cells ([3] and our unpublished data). It remains unclear why Pon showed such potency and synergism with Tra among all TKIs. It is likely that at the endogenous level, FGFR signaling plays an important role in VQ MM. Alternatively, Pon is a relatively more potent TKI compared to others; the clinical dose of Pon is indeed lower than those of other TKIs [23]. However, considering 1mM is a fairly high concentration *in vivo*, we did not pursue other TKIs at higher concentrations.

Despite the strong synergistic effects of Tra + Pon *in vitro*, the *in vivo* effect was only moderately better than Tra alone (Figure 3). We postulated that the anti-myeloma effects of combination Tra/Pon treatment were abrogated by their unfavorable impacts on non-myeloma cells, such as myeloma killing cytotoxic CD8 T cells. Indeed, Pon, but not Tra, prevented CD8 proliferation and activation (Figure 4B-4E). Our data suggest that the negative impact of Pon treatment on T cells may counteract its MM-killing synergism with Tra *in vivo*. It is possible that other yet unidentified negative effects of these drugs exist. The complexity of MM *in vivo* warrants a comprehensive evaluation of agents on MM cells and other important anti-MM immune cells during therapy development.

Methods

Mice. CD45.1⁺ transplant recipients were purchased from Jackson Laboratory (stock # 002014) and maintained at Biotron Animal Research Services facility, University of Wisconsin-Madison. Mice were 8-12 weeks old at time of transplant and male and female mice were used in approximately equal proportion. All animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory

Animals and approved by an Animal Care and Use Committee at UW-Madison. The program is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. All animal experiments in this study are reported in accordance with ARRIVE guidelines (<https://arriveguidelines.org>).

Drug screening of VQ cell lines

The Approved Oncology Drugs (AOD) IX drug panel was provided to the University of Wisconsin-Madison (UW-Madison) by the National Cancer Institute's Division of Treatment & Diagnosis. Dilution and preparation of the AOX IX panel in 384 well plates was carried out by UW-Madison's Small Molecule Screening Facility (SMSF).

VQ 4935 and 4938 cell lines were cultured in IMDM (Corning, 15-016-CM) containing 10% FBS (Gibco, Cat No. 16000), 1X antibiotics, and 10ng/ml human recombinant IL6 (PeproTech, 200-06) at 37°C. They were seeded 50 μ L/well at a density of 5×10^5 cells/ml in a 384-well plate using a MicroFlo Select Reagent Dispenser (BioTek). 48 hours later, cell viability was evaluated using CellTiter-Glo assay (Cat No. G7573, Promega). Chemiluminescence was measured using an ENSPIRE Plate Reader (Perkin Elmer). Z' Factor was calculated as previously described [4].

IC₅₀ values were calculated via logistic regression with variable slope using GraphPad Prism v9.2.0 software.

Drug Combination Studies

Drug combination studies were set up using a 5x5 matrix design around IC₅₀ of each drug in VQ 4935 and 4938 cell lines. Synergy was calculated using ZIP delta score via the SynergyFinder online tool (<https://synergyfinder.fimm.fi>) [13]. Combination Index scores were calculated using Compusyn v1.0 software as previously described [14].

Transplantation of myeloma cells

Donor cells from two moribund VQ-D1 MM bearing mice were pooled equally and resuspended in 100 μ L of PBS containing 2% mouse serum (Jackson ImmunoResearch, 015-000-120). Eight- to fourteen-week-old CD45.1⁺ recipient mice were sub-lethally irradiated at 4.0 Gy using an X-RAD 320 Irradiator (Precision X-Ray Inc.) and transplanted with 5×10^5 of donor cells via intracardiac injection.

Serum protein electrophoresis (SPEP)

Mice were retro-orbitally bled with plain micro hematocrit tubes (Bris, IS012772). Blood samples were spun in microtainer tubes (BD, 365967) at 4,000x g for 10 minutes to collect serum. Serum was loaded into Hydragel agarose gel (Sebia, 4140) and processed using the Hydrasys instrument (Sebia) following the manufacturer's instruction. The processed film was scanned and pixel density of Albumin and γ -globulin bands were quantified using Adobe Photoshop.

Complete blood count

Peripheral blood samples were collected via retro-orbital bleeding and analyzed with a Hemavet 950FS (Drew Scientific).

Small compound treatment

For *in vivo* bortezomib treatment, bortezomib (Selleck) was dissolved in sterile PBS and administered at 0.5mg/kg twice a week for four weeks via intra-peritoneal (IP) injection.

For *in vivo* treatment of carfilzomib, dexamethasone, trametinib, and GSK525762, carfilzomib (Selleck) was dissolved in sterile PBS and administered at 16mg/kg once a week via IP injection for two weeks. Dexamethasone (Selleck) was dissolved in sterile PBS and administered at 1mg/kg once a week via IP injection for two weeks. Trametinib (Chemitec) was dissolved in 0.5% hydroxypropylmethylcellulose (Sigma) and 0.2% Tween-80 (Sigma) in distilled water (pH 8.0) and given orally at 0.5mg/kg every morning for one week. GSK525762 (Chemitec) was dissolved in 1% methylcellulose (Sigma) containing 0.2% SDS and given orally at 15mg/kg every evening for one week.

For *in vivo* treatment of trametinib and ponatinib, both compounds were dissolved in 0.5% hydroxypropylmethylcellulose (Sigma) and 0.2% Tween-80 (Sigma) in distilled water (pH 8.0) and administered at 0.2mg/kg and 10.0mg/kg respectively, via oral gavage daily. In a second treatment experiment, trametinib and ponatinib were dissolved in 0.5% hydroxypropylmethylcellulose (Sigma) and 0.2% Tween-80 (Sigma) in distilled water (pH 8.0) and administered at 0.5mg/kg and 10.0mg/kg, respectively, in 28 day cycles with 21 days of treatment followed by 7 days of rest.

Mice were not allocated to treatment groups in a blinded manner but were instead allocated so that G/A and CBC parameters were statistically similar between each group (One-way Analysis of Variance with Tukey-Kramer test). Small compounds were not administered to animals in a blinded manner due to necessary daily preparation of working concentrations for treatment. Animal care staff were blinded to experimental groups during animal assessment. Post-experiment data analysis was not blinded.

CD8 T cell activation assay

CD8 T cells were purified from total splenocytes of 8-14 weeks old C57BL/6J mice using the Mouse CD8 α ⁺ T Cell Isolation Kit (Miletnyi Biotec, 130-104-75) and labeled with CFSE (eBioscience, 65-0850-84) as described [24]. CD8 T cells were cultured in RPMI-1640 (Corning, 15-041-CV) containing 10% FBS, 1X Antibiotics, 1X GlutaMAX (Gibco, 35050061), 1X MEM non-essential amino acids solution (Gibco, 11140050), 1mM Sodium Pyruvate (Gibco, 11360070), and 50 μ M 2-Mercaptoethanol (Gibco, 21985-23). T cells were activated in the presence or absence of trametinib and ponatinib using plate-bound α -CD3 (eBioscience, 17A2; 50 μ L of 10 μ g/mL solution incubated at 4°C overnight) and soluble α -CD28 (eBioscience, 17A2; 5 μ g/mL) for 48 hours prior to analysis.

Flow cytometric analysis of hematopoietic tissues

Flow cytometric analysis of surface antigens on hematopoietic cells was performed as previously described [25]. Stained cells were analyzed on a LSRII Fortessa (BD Biosciences). Directly conjugated antibodies specific for the following mouse surface antigens were purchased from Biolegend unless specified: CD3(17A2), CD4 (eBioscience, GK1.5), CD8 (eBioscience, 53-6.7), CD62L(MEL-14), CD44(IM7), PD1 (29F.1A12), TIGIT(GIGD7), LAG3(C9B7W), DNAM-1(TX42.1), CD69 (eBioscience, H1.2F3).

Statistics

For Kaplan–Meier survival curves, survival differences between groups were assessed with the log-rank test, assuming significance at $p < 0.05$. Unpaired, two-way t Test was used to determine significant differences between two groups unless specified. One-way Analysis of Variance with Tukey-Kramer test was used to determine the significance between multiple data sets simultaneously unless specified, assuming significance at $p < 0.05$. Statistical analysis was carried out using GraphPad Prism v9.1.

Declarations

Data availability.

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Acknowledgements and Funding:

We would like to thank the University of Wisconsin Carbone Comprehensive Cancer Center (UWCCC) for use of its Shared Services (Small Molecule Screening Facility, Flow Cytometry Laboratory, Transgenic Animal Facility, and Experimental Pathology Laboratory) to complete this research. We would also like to thank the National Cancer Institute (NCI)/Division of Cancer Treatment and Diagnosis (DCTD)/Developmental Therapeutics Program (DTP) (<http://dtp.cancer.gov>) for kindly providing the NCI AOD IX drug library. This work was supported by a postdoctoral fellowship from the Multiple Myeloma Research Foundation to OJ, NIH grant T32 GM081061 to EF, U01AI12499 and R21AI149793 to MS, R01CA212413 to AR, R01CA252937 to FA, and R01CA152108 to JZ. This work was also supported in part by NIH/NCI P30 CA014520–UW Comprehensive Cancer Center Support and the NIH Shared Instrument Grant 1S100OD018202-01 (BD LSR Fortessa).

Author Contributions

Conception and design: E. Flietner, Z. Wen, and J. Zhang

Acquisition, analysis, and interpretation of cell line and mouse data: E. Flietner, Z. Wen, A. Rajagopalan, O. Jung, J. Weisner, X. You, Y. Zou

Writing, review, and/or revision of the manuscript: E. Flietner, Z. Wen, N. Callander, A. Rapraeger, M. Suresh, F. Asimakopoulos, J. Zhang

Technical or material support: B. Kingstad-Bakke, M. Suresh

Study supervision: J. Zhang

Competing Interests:

We declare that no conflict of interest exists.

References

1. Nijhof, I. S., van de Donk, N. W. C. J., Zweegman, S. & Lokhorst, H. M. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. *Drugs* **78**, 19–37 (2018).
2. Kortüm, K. M. *et al.* Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. *Blood* **128**, 1226–1233 (2016).
3. Wen, Z. *et al.* Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice. *Blood* **137**, 61–74 (2021).
4. Zhang, J.-H. & Oldenburg, K. R. Z-Factor. in *Encyclopedia of Cancer* (ed. Schwab, M.) 3227–3228 (Springer, 2009). doi:10.1007/978-3-540-47648-1_6298.
5. Swan, D., Gurney, M., Krawczyk, J., Ryan, A. E. & O'Dwyer, M. Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma. *Hemasphere* **4**, e350 (2020).
6. Fink, E. C. *et al.* CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. *Blood* **132**, 1535–1544 (2018).
7. Chesi, M. *et al.* Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. *Blood* **120**, 376–385 (2012).
8. Kumar, S. *et al.* Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. *Blood* **130**, 2401–2409 (2017).
9. Besse, A. *et al.* Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors. *Cell Chemical Biology* **26**, 340-351.e3 (2019).
10. Mulligan, G. *et al.* Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. *Blood* **123**, 632–639 (2014).
11. Mirguet, O. *et al.* Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. *J Med Chem* **56**, 7501–7515 (2013).
12. Tan, F. H., Putoczki, T. L., Stylli, S. S. & Luwor, R. B. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. *Onco Targets Ther* **12**, 635–645 (2019).
13. Ianevski, A., He, L., Aittokallio, T. & Tang, J. SynergyFinder: a web application for analyzing drug combination dose–response matrix data. *Bioinformatics* **33**, 2413–2415 (2017).
14. Chou, T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. *Cancer Res* **70**, 440–446 (2010).

15. D'Souza, C., Prince, H. M. & Neeson, P. J. Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs. *Frontiers in Immunology* **12**, 594 (2021).
16. Marinelli Busilacchi, E. *et al.* Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study. *Biol. Blood Marrow Transplant.* **24**, 267–275 (2018).
17. Weichsel, R. *et al.* Profound inhibition of antigen-specific T-cell effector functions by dasatinib. *Clin Cancer Res* **14**, 2484–2491 (2008).
18. Leonard, J. T. *et al.* Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL. *Blood* **137**, 939–944 (2021).
19. Luo, L. *et al.* Kras-deficient T cells attenuate graft-versus-host disease but retain graft-versus-leukemia activity. *J Immunol* **205**, 3480–3490 (2020).
20. Zeiser, R., Andrlová, H. & Meiss, F. Trametinib (GSK1120212). in *Small Molecules in Oncology* (ed. Martens, U. M.) 91–100 (Springer International Publishing, 2018). doi:10.1007/978-3-319-91442-8_7.
21. Gozgit, J. M. *et al.* Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models. *Mol Cancer Ther* **11**, 690–699 (2012).
22. Kalff, A. & Spencer, A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. *Blood Cancer Journal* **2**, e89–e89 (2012).
23. García-Gutiérrez, V. & Hernández-Boluda, J. C. Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety. *Front Oncol* **9**, 603 (2019).
24. Quah, B. J. C. & Parish, C. R. The Use of Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE) to Monitor Lymphocyte Proliferation. *JoVE (Journal of Visualized Experiments)* e2259 (2010) doi:10.3791/2259.
25. Wang JY, Liu YG, Li ZY, *et al.* Endogenous oncogenic Nras mutation leads to aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. *Blood*. 2010;116(26):5991–6002.

Figures

Figure 1-Zhang

Figure 1

Re-purpose screening identifies de novo resistance of VQ MM cells to venetoclax. (A) Schematic of drug screening procedure against VQ myeloma cells. (B) AOD IX screening results for compounds at 100nM and 1000nM concentration alone or in the presence of 10nM Trametinib. Results are plotted as Log2 fold change in viability relative to DMSO-treated control wells as measured by CellTiter-Glo Luminescent Assay after 48 hours of treatment. Notable compounds are highlighted-see accompanying tables in panel

C. (C) Table detailing selected positive, false negative, and true negative hits from the AOD IX library as highlighted in (B). (D) VQ 4935 and 4938 cells were treated with the indicated concentration of venetoclax for 48 hours. Relative viability to DMSO treated control was then measured using the CellTiter-Glo assay. IC_{50} values were calculated by logistic regression using the GraphPad Prism software. (E) Transcript levels of anti-apoptotic genes BCL2 and MCL1 in CD138⁺ B220⁻ cells from control bone marrow (BM) or VQ recipient BM. FPKM, Fragments Per Kilobase of transcript per Million mapped reads. (F) Ratios of Bcl2:Bcl2l1 and Bcl2:Mcl1 gene expression levels. Results are presented as mean + SD. *, $p < 0.05$.

Figure 2-Zhang

Figure 2

Ponatinib, but not other TKIs, synergizes with trametinib *in vitro*. (A) Relative viability results for tyrosine kinase inhibitors (TKIs) from AOD IX panel at 100nM and 1000nM concentration alone or in the presence of 10nM trametinib, as in Figure 1A. (B) Screening results of TKIs as single agents and with 10nM trametinib. Trametinib and Ponatinib are highlighted as in Figure 2A. Of note, 10nM trametinib yielded ~50% viability relative to DMSO control. (C-E) VQ 4935 and 4938 cells were treated with the indicated

concentrations of two compounds for 48 hours. Relative viability to DMSO treated control was then measured using the CellTiter-Glo assay. (C) Dose-response results for ponatinib against VQ 4935 and 4938 cell lines. IC₅₀ values were calculated by logistic regression using the GraphPad Prism software. (D) Selected viability results for combination treatment of trametinib (Tra) and ponatinib (Pon) against VQ 4935 and 4938 cells. (E) ZIP synergy plots of Tra and Pon in VQ 4935 and 4938 cells. Zip Synergy scores were generated using the SynergyFinder online tool.

Figure 3

Combination trametinib and ponatinib treatment prolongs VQ myeloma survival. (A) Schematic of pre-clinical treatment groups and *in vivo* drug dosages. Mice were treated with the indicated compounds daily as described in Materials and Methods. (B) Serum protein electrophoresis was performed to quantify the γ -globulin/Albumin (G/A) ratios in VQ recipient mice before treatment and at day 21 of treatment. Note: Two Vehicle-treated recipients were found dead and unable to be analyzed. (C) Kaplan-Meier survival curves were plotted against days after treatment. Log-rank test was performed. (D) Schematic of pre-clinical treatment groups and *in vivo* drug dosages. Mice were treated with the indicated compounds in 28-day cycles (3-weeks on and one-week off) as described in Materials and Methods. (E) Serum protein electrophoresis was performed to quantify the G/A ratios in VQ recipient mice before treatment (Pre) and at day 21 of treatment. Note: One Vehicle-treated recipient was found dead and unable to be analyzed. (F) Kaplan-Meier survival curves were plotted against days after treatment. Log-rank test was performed. Note: One vehicle-treated animal was euthanized for reasons unrelated to treatment study and was excluded from analysis. *, p<0.05; **, p<0.01; ***, p<0.001.

Figure 4

Ponatinib, but not trametinib, blocks CD8 T cell proliferation and activation *in vitro*. (A) Experimental schematic for CD8 T cell proliferation and activation assay. CD8 T cells isolated from the spleens of C57BL/6J mice were stained with CFSE and cultured in the presence of plate-bound α -CD3 and soluble α -CD28, along with the indicated concentrations of trametinib and ponatinib, for 48 hours. Cells were then analyzed using flow cytometry. Statistical differences between multiple groups were determined via one-

way ANOVA with Tukey's post-test analysis. (B) Proliferation Index was calculated for each group via FCS Express v7.08 software. (C-E) Quantification of CD69⁺ (C), DNAM-1⁺ (D), and PD-1⁺ (E) CD8 T cells. Results are presented as mean + SD. *, p<0.05; **, p<0.01; ***, p<0.001

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [FigS1.pdf](#)
- [FigS2.pdf](#)
- [FigS3.pdf](#)
- [FigS4.pdf](#)
- [FigS5.pdf](#)
- [FigS6.pdf](#)
- [FigS7.pdf](#)
- [TableS1.docx](#)
- [Supplemental012122.docx](#)